3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Brain Neoplasms
15
Glioblastoma
12
Gliosarcoma
9
Glioma
8
Central Nervous System Neoplasms
7
Astrocytoma
7
Oligodendroglioma
6
Meningioma
4
Neurofibromatoses
3
Glioma, Subependymal
3
Neurofibroma, Plexiform
2
Gastrointestinal Stromal Tumors
2
Ependymoma
2
Osteosarcoma
1
Neurofibrosarcoma
1
Neurofibroma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Nerve Sheath Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Adenocarcinoma
1
Interventions
mirdametinib
2
tipifarnib
1
talimogene laherparepvec
1
peginterferon alfa-2b
1
nilotinib
1
binimetinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Vincristine
1
Temozolomide
1
Talaporfin
1
Sirolimus
1
Restraint, Physical
1
Ranibizumab
1
Radiosurgery
1
Photochemotherapy
1
Neurofibromin 1
1
Mn-PyC3A
1
Imatinib Mesylate
1
Everolimus
1
Elasticity Imaging Techniques
1
Deoxycholic Acid
1
Cryotherapy
1
Celecoxib
1
Aminolevulinic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurofibroma
×
Imatinib Mesylate
×
CNS
×
Clear all
NCT01140360
2017-07-02
0908-09
Indiana University
Phase 1/2
Completed
21 enrolled
8 charts